FDA Approves Merck's KEYTRUDA[R] (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients Approval Received Less Than One Month Following Submission of sBLA Application Based on Results of [...]